Figure 2From: Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesityPercentage of patients achieving composite endpoint of HbA1c ≤ 7.0%, no hypoglycemia, no weight gain.Back to article page